The DOI matches its Crossref record; 105 of the 105 references it cites were found in a registry or an index.
Cancer gene therapy: fringe or cutting edge?
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607 · cited 1×
“Loss of TP53 increases the rates of spontaneous cancers tremendousl”
BackgroundDruker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243
An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells
Bischoff, J. R., Kirn, D. H., Williams, A., Heise, C., Horn, S., Muna, M., Ng, L., Nye, J. A., Sampson-Johannes, A., Fattaey, A., et al. (1996) · Science · doi:10.1126/science.274.5286.373 · Cited by 1,760
Self-citationThe EGF receptor family as targets for cancer therapy
Mendelsohn, J., & Baselga, J. (2000) · Oncogene · doi:10.1038/sj.onc.1204082 · Cited by 1,340
Khuri, F. R., Nemunaitis, J., Ganly, I., Arseneau, J., Tannock, I. F., Romel, L., Gore, M., Ironside, J., MacDougall, R. H., Heise, C., et al. (2000) · Nature Medicine · doi:10.1038/78638 · Cited by 1,101
Markert, J. M., Medlock, M. D., Rabkin, S. D., Gillespie, G. Y., Todo, T., Hunter, W. D., Palmer, C. A., Feigenbaum, F., Tornatore, C., Tufaro, F., et al. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301205 · Cited by 976
Moolten, F. L. (1986) · PubMed · Cited by 972
Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo
Sebolt-Leopold, J. S., Dudley, D. T., Herrera, R., Becelaere, K. V., Wiland, A., Gowan, R. C., Tecle, H., Barrett, S. D., Bridges, A., Przybranowski, S., et al. (1999) · Nature Medicine · doi:10.1038/10533 · Cited by 970
Essential role for oncogenic Ras in tumour maintenance
Chin, L., Tam, A., Pomerantz, J., Wong, M., Holash, J., Bardeesy, N., Shen, Q., O'Hagan, R., Pantginis, J., Zhou, H., et al. (1999) · Nature · doi:10.1038/22788 · Cited by 875
Induction of the growth inhibitor IGF-binding protein 3 by p53
Buckbinder, L., Talbott, R., Velasco-Miguel, S., Takenaka, I., Faha, B., Seizinger, B. R., & Kley, N. (1995) · Nature · doi:10.1038/377646a0 · Cited by 869
Cited by
Progress and problems with the use of viral vectors for gene therapy
Thomas, C. E., Ehrhardt, A., & Kay, M. A. (2003) · Nature Reviews Genetics · doi:10.1038/nrg1066 · Cited by 2,501
Addiction to Oncogenes--the Achilles Heal of Cancer
Weinstein, I. B. (2002) · Science · doi:10.1126/science.1073096 · Cited by 1,728
The RB and p53 pathways in cancer
Sherr, C. J., & McCormick, F. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00102-2 · Cited by 1,690
“Restoration of p53 function in p53 null tumors, which can potentially be achieved through genetic or pharmacologic methods, can directly induce apoptosis and reestablish responses to cytotoxic drugs (McCormick, 2001; Lane and Lain, 2002).”
BackgroundInfluentialSelf-citationTranscription factors as targets for cancer therapy
Darnell, J. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc906 · Cited by 1,194
TRAIL and apoptosis induction by TNF-family death receptors
Wang, S., & El-Deiry, W. S. (2003) · Oncogene · doi:10.1038/sj.onc.1207232 · Cited by 871
Apoptosis and melanoma chemoresistance
Soengas, M. S., & Lowe, S. W. (2003) · Oncogene · doi:10.1038/sj.onc.1206454 · Cited by 826
Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapy
Weinstein, I. B., & Joe, A. K. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0558 · Cited by 705
Apoptosis: a basic biological phenomenon with wide‐ranging implications in human disease
FADEEL, B., & ORRENIUS, S. (2005) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2005.01570.x · Cited by 698
Trang, P., Wiggins, J. F., Daige, C. L., Cho, C., Omotola, M., Brown, D., Weidhaas, J. B., Bader, A. G., & Slack, F. J. (2011) · Molecular Therapy · doi:10.1038/mt.2011.48 · Cited by 667
Biomedical Applications of Zinc Oxide Nanomaterials
Zhang, Y., Nayak, T., Hong, H., & Cai, W. (2013) · Current Molecular Medicine · doi:10.2174/1566524013666131111130058 · Cited by 651
The Promise of MicroRNA Replacement Therapy
Bader, A. G., Brown, D., & Winkler, M. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2010 · Cited by 617
Thomas, M., & Klibanov, A. M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1233634100 · Cited by 549
Graphene: a versatile nanoplatform for biomedical applications
Zhang, Y., Nayak, T. R., Hong, H., & Cai, W. (2012) · Nanoscale · doi:10.1039/c2nr31040f · Cited by 530
Enhancing polyethylenimine's delivery of plasmid DNA into mammalian cells
Thomas, M., & Klibanov, A. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192581499 · Cited by 483
Ghosh, P. S., Kim, C.-K., Han, G., Forbes, N. S., & Rotello, V. M. (2008) · ACS Nano · doi:10.1021/nn800507t · Cited by 459
Oncogene addiction: setting the stage for molecularly targeted cancer therapy
Sharma, S. V., & Settleman, J. (2007) · Genes & Development · doi:10.1101/gad.1609907 · Cited by 441
A Review on Green Synthesis, Biomedical Applications, and Toxicity Studies of ZnO NPs
Kalpana, V. N., & Devi Rajeswari, V. (2018) · Bioinorganic Chemistry and Applications · doi:10.1155/2018/3569758 · Cited by 436
Cell transfection in vitro and in vivo with nontoxic TAT peptide-liposome–DNA complexes
Torchilin, V. P., Levchenko, T. S., Rammohan, R., Volodina, N., Papahadjopoulos-Sternberg, B., & D'Souza, G. G. M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0435906100 · Cited by 419
Kurki, S., Peltonen, K., Latonen, L., Kiviharju, T. M., Ojala, P. M., Meek, D., & Laiho, M. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00110-2 · Cited by 416
Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer
Kirn, D. H., & Thorne, S. H. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2545 · Cited by 402
Müller, O. J., Kaul, F., Weitzman, M. D., Pasqualini, R., Arap, W., Kleinschmidt, J. A., & Trepel, M. (2003) · Nature Biotechnology · doi:10.1038/nbt856 · Cited by 410
Nanomedicine of synergistic drug combinations for cancer therapy – Strategies and perspectives
Zhang, R. X., Wong, H. L., Xue, H. Y., Eoh, J. Y., & Wu, X. Y. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.06.012 · Cited by 380
Kim, M.-H., Na, H.-K., Kim, Y.-K., Ryoo, S.-R., Cho, H. S., Lee, K. E., Jeon, H., Ryoo, R., & Min, D.-H. (2011) · ACS Nano · doi:10.1021/nn103130q · Cited by 364
Strategies for reversing drug resistance
Fojo, T., & Bates, S. (2003) · Oncogene · doi:10.1038/sj.onc.1206951 · Cited by 357
Viral gene therapy strategies: from basic science to clinical application
Young, L. S., Searle, P. F., Onion, D., & Mautner, V. (2006) · The Journal of Pathology · doi:10.1002/path.1896 · Cited by 313
The Molecular and Genetic Basis of Neurological Tumours
Zhu, Y., & Parada, L. F. (2002) · Nature Reviews Cancer · doi:10.1038/nrc866 · Cited by 309
Treating cancer with microRNA replacement therapy: A literature review
Hosseinahli, N., Aghapour, M., Duijf, P. H. G., & Baradaran, B. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26514 · Cited by 305
Viral homologs of BCL-2: role of apoptosis in the regulation of virus infection
Cuconati, A., & White, E. (2002) · Genes & Development · doi:10.1101/gad.1012702 · Cited by 286
Pullulan and pullulan derivatives as promising biomolecules for drug and gene targeting
Singh, R. S., Kaur, N., & Kennedy, J. F. (2015) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2015.01.032 · Cited by 262
Intravascular adenoviral agents in cancer patients: Lessons from clinical trials
Reid, T., Warren, R., & Kirn, D. (2002) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700539 · Cited by 258
Reactivation of mutant p53: molecular mechanisms and therapeutic potential
Selivanova, G., & Wiman, K. G. (2007) · Oncogene · doi:10.1038/sj.onc.1210295 · Cited by 186
Taki, M., Kagawa, S., Nishizaki, M., Mizuguchi, H., Hayakawa, T., Kyo, S., Nagai, K., Urata, Y., Tanaka, N., & Fujiwara, T. (2005) · Oncogene · doi:10.1038/sj.onc.1208460 · Cited by 86
Somatostatin Receptor Based Imaging and Radionuclide Therapy
Xu, C., & Zhang, H. (2015) · BioMed Research International · doi:10.1155/2015/917968 · Cited by 49
Metadata
- Authors
- McCormick, F.
- Venue
- Nature Reviews Cancer
- Published
- 2001-11-01
- Volume
- 1
- Issue
- 2
- Pages
- 130-141
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W1540542144
- Cited by
- 346
- References
- 105
- FWCI
- 2.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.